Benefits
Mood support
SAMe is a methyl donor used to make mood-related neurotransmitters such as serotonin and dopamine. In randomized trials it has been studied for supporting a healthy, positive mood, both on its own and alongside standard care under medical supervision.
Joint comfort
In people with osteoarthritis of the knee or hip, SAMe has been studied for easing joint discomfort and supporting everyday joint function, performing comparably to a common anti-inflammatory in one head-to-head trial, though it works more gradually.
Liver support
SAMe is central to methylation reactions in the liver and to producing glutathione, the liver's main antioxidant. It has been studied and reviewed for supporting healthy liver function, including in cholestasis and chronic liver conditions.
Fibromyalgia comfort
In a controlled trial in fibromyalgia, oral SAMe was studied for easing pain, fatigue, and morning stiffness versus placebo, pointing to a possible role in supporting comfort and daily function.
Mechanism of action
Methyl donation
SAMe is the body's universal methyl donor, handing off methyl groups to make neurotransmitters, phospholipids, and creatine and to methylate DNA and proteins that regulate gene activity, central to mood and cell signaling.
Transsulfuration and glutathione
After donating its methyl group, SAMe feeds the transsulfuration pathway that produces glutathione, the main cellular antioxidant, supporting liver detoxification and defense against oxidative stress.
Cartilage and proteoglycan support
SAMe promotes synthesis of the proteoglycans that keep joint cartilage hydrated and resilient and helps temper pro-inflammatory signaling, which may underlie its joint-comfort effects.
Polyamine synthesis
SAMe is a precursor for polyamines involved in tissue growth and repair, including cartilage and nerve tissue, complementing its methylation and antioxidant roles.
Clinical trials
Systematic review and meta-analysis of 23 randomized trials of S-adenosyl-L-methionine in depressed patients. (Prog Neuropsychopharmacol Biol Psychiatry, 2024)
Adults with depression across 23 randomized controlled trials.
SAMe was significantly better than placebo as a standalone option, with a moderate benefit; as an add-on to antidepressants it was not clearly better than antidepressants alone. Overall the pooled evidence supports SAMe's mood use.
Double-blind randomized controlled trial comparing SAMe, escitalopram, and placebo in 144 adults with major depression over 12 weeks. (J Affect Disord, 2014)
144 adults with major depression.
SAMe as a standalone treatment separated from placebo, with higher response and remission rates over 12 weeks. It supports SAMe as a mood option, though the trial was modest in size.
Cochrane systematic review of S-adenosylmethionine for osteoarthritis of the knee or hip. (Cochrane Database of Systematic Reviews, 2009)
Adults with knee or hip osteoarthritis.
Pooled trials suggested SAMe may reduce pain and improve function, but the review judged the evidence too limited to recommend routine use. The effects looked potentially meaningful, so results cautiously support its joint-comfort positioning.
Double-blind crossover trial comparing SAMe (1,200 mg/day) with celecoxib in adults with knee osteoarthritis. (BMC Musculoskelet Disord, 2004)
Adults with knee osteoarthritis.
SAMe produced pain and function improvements comparable to the anti-inflammatory drug celecoxib, but with a slower onset of about a month. It supports SAMe as a slower-acting joint-comfort option.
Double-blind, placebo-controlled trial of oral S-adenosylmethionine in patients with primary fibromyalgia. (Scand J Rheumatol, 1991)
Adults with primary fibromyalgia.
Oral SAMe improved pain, fatigue, and morning stiffness compared with placebo over the study period, supporting a role in fibromyalgia comfort. The trial was small, so the findings are preliminary.